Company: CRL
Filing Date: 2025-09-19
Form Type: 8-K/A
Source: 0000950103-25-011896
Chunk: 1

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-09-19
Form: 8-K/A
Chunk 1
---
 use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐

| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |

(c) On September 16, 2025, Charles River Laboratories International,
Inc. (the “Company”) filed a current report on Form 8-K under item 5.02 to report the resignation of Flavia H. Pease as Corporate
Executive Vice President, Chief Financial Officer of the Company and the appointment of Michael G. Knell as interim Chief Financial Officer
of the Company. The Company is filing this Form 8-K/A to disclose details of Mr. Knell’s
compensation that were not determined at the time of the original filing.

On September 15, 2025, in connection with Mr. Knell’s
appointment as interim Chief Financial Officer and interim principal financial officer of the Company, the Compensation Committee of
the Company’s Board of Directors approved the following changes to Mr. Knell’s compensation package: (i) an increase in
annual base salary to $500,000, effective September 28, 2025; (ii) a $10,000 monthly cash payment to be paid during Mr.
Knell’s term of service as interim Chief Financial Officer, effective October 1, 2025; and (iii) a one-time grant of
restricted stock units of the Company’s common stock with a grant value of $500,000, to be granted on November 6, 2025 (the
first business day following the press release with respect to financial results for the third fiscal quarter of 2025), with 50% to
vest on the first anniversary of the grant date and the remaining 50% to vest on the second anniversary of the grant date.

<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Date: | September 19, 2025 | By: | CHARLES RIVER LABORATORIES INTERNATIONAL, INC.                  
 /s/ Matthew L. Daniel                                           |
|:------|:-------------------|:----|:----------------------------------------------------------------|
|       |                    |     | Matthew L. Daniel,